[go: up one dir, main page]

NO2003010I2 - Pegfilgrastim - Google Patents

Pegfilgrastim

Info

Publication number
NO2003010I2
NO2003010I2 NO2003010C NO2003010C NO2003010I2 NO 2003010 I2 NO2003010 I2 NO 2003010I2 NO 2003010 C NO2003010 C NO 2003010C NO 2003010 C NO2003010 C NO 2003010C NO 2003010 I2 NO2003010 I2 NO 2003010I2
Authority
NO
Norway
Prior art keywords
hpg
csf
disclosed
procaryotic
expression
Prior art date
Application number
NO2003010C
Other languages
English (en)
Other versions
NO2003010I1 (no
Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27118107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2003010(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kirin Amgen Inc filed Critical Kirin Amgen Inc
Publication of NO2003010I1 publication Critical patent/NO2003010I1/no
Publication of NO2003010I2 publication Critical patent/NO2003010I2/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO2003010C 1985-08-23 2003-12-09 Pegfilgrastim NO2003010I2 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76895985A 1985-08-23 1985-08-23
US06/835,548 US4810643A (en) 1985-08-23 1986-03-03 Production of pluripotent granulocyte colony-stimulating factor
PCT/US1986/001708 WO1987001132A1 (en) 1985-08-23 1986-08-22 Production of pluripotent granulocyte colony-stimulating factor

Publications (2)

Publication Number Publication Date
NO2003010I1 NO2003010I1 (no) 2004-01-26
NO2003010I2 true NO2003010I2 (no) 2007-07-09

Family

ID=27118107

Family Applications (6)

Application Number Title Priority Date Filing Date
NO871679A NO303544B1 (no) 1985-08-23 1987-04-22 FremgangsmÕte for fremstilling av et polypeptid med Ún eller flere av de hematopoietiske biologiske egenskaper til granulocyttkolonistimulerende faktor (hpG-CSF)
NO19982132A NO314902B1 (no) 1985-08-23 1998-05-11 Biologisk funksjonelt plasmid eller virus-DNA-vektor som koder for en analog av granulocyttkolonistimulerende faktor (hpG-CSF), samtprokaryot eller eukaryot vertscelle
NO20032250A NO318755B1 (no) 1985-08-23 2003-05-19 Anvendelse av et hpG-CSF-polypeptid til fremstilling av et medikament for a stanse proliferasjon av leukemiceller
NO2003008C NO2003008I1 (no) 1985-08-23 2003-11-13 Fremgangsmaate for fremstilling av et polypeptid med én eller flere av de hematopoietiske biologiskeegenskaper til grnulocyttkolonistimulerende faktor(hpg-csf)
NO2003010C NO2003010I2 (no) 1985-08-23 2003-12-09 Pegfilgrastim
NO20045548A NO20045548L (no) 1985-08-23 2004-12-17 Fremgangsmate for fremstilling av et hpG-CSF-polypeptidprodukt, samt anvendelse derav til fremstilling av et medikament for induksjon av proliferasjonen av humane benmargsceller

Family Applications Before (4)

Application Number Title Priority Date Filing Date
NO871679A NO303544B1 (no) 1985-08-23 1987-04-22 FremgangsmÕte for fremstilling av et polypeptid med Ún eller flere av de hematopoietiske biologiske egenskaper til granulocyttkolonistimulerende faktor (hpG-CSF)
NO19982132A NO314902B1 (no) 1985-08-23 1998-05-11 Biologisk funksjonelt plasmid eller virus-DNA-vektor som koder for en analog av granulocyttkolonistimulerende faktor (hpG-CSF), samtprokaryot eller eukaryot vertscelle
NO20032250A NO318755B1 (no) 1985-08-23 2003-05-19 Anvendelse av et hpG-CSF-polypeptid til fremstilling av et medikament for a stanse proliferasjon av leukemiceller
NO2003008C NO2003008I1 (no) 1985-08-23 2003-11-13 Fremgangsmaate for fremstilling av et polypeptid med én eller flere av de hematopoietiske biologiskeegenskaper til grnulocyttkolonistimulerende faktor(hpg-csf)

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20045548A NO20045548L (no) 1985-08-23 2004-12-17 Fremgangsmate for fremstilling av et hpG-CSF-polypeptidprodukt, samt anvendelse derav til fremstilling av et medikament for induksjon av proliferasjonen av humane benmargsceller

Country Status (23)

Country Link
US (5) US4810643A (no)
EP (1) EP0237545B2 (no)
JP (11) JP2527365B2 (no)
KR (1) KR880700071A (no)
CN (1) CN1020924C (no)
AT (1) ATE332375T1 (no)
AU (1) AU6334686A (no)
CA (1) CA1341537C (no)
CY (1) CY1642A (no)
DE (1) DE3650788T2 (no)
DK (1) DK174980B1 (no)
ES (1) ES2001883A6 (no)
FI (3) FI105191B (no)
GR (1) GR862185B (no)
IL (1) IL79805A (no)
MX (1) MX9202992A (no)
NL (1) NL930127I1 (no)
NO (6) NO303544B1 (no)
NZ (1) NZ217334A (no)
PT (1) PT83242B (no)
SA (1) SA92130186B1 (no)
SG (2) SG48964A1 (no)
WO (1) WO1987001132A1 (no)

Families Citing this family (346)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
ATE65798T1 (de) * 1985-02-08 1991-08-15 Chugai Pharmaceutical Co Ltd Menschlicher granuloxcyt-koloniestimulierungsfaktor.
US5532341A (en) * 1985-03-28 1996-07-02 Sloan-Kettering Institute For Cancer Research Human pluripotent hematopoietic colony stimulating factor
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6004548A (en) * 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
NZ218336A (en) * 1985-12-09 1991-08-27 Kirin Amgen Inc Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf)
DK203187A (da) * 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
GR871067B (en) * 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
US5186931A (en) * 1986-08-06 1993-02-16 Ajinomoto Co., Inc. Composition and method for supporting bone marrow transplantation
AU7675487A (en) * 1986-08-11 1988-05-19 Cetus Corporation Expression of granulocyte colony-stimulating factor
JPH0618781B2 (ja) * 1986-10-18 1994-03-16 中外製薬株式会社 感染症治療剤
US6238889B1 (en) * 1986-12-16 2001-05-29 Dsm N.V. Molecular cloning and expression of the Pro8 isoform of human IL-3
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5714581A (en) * 1986-12-23 1998-02-03 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
JP2618618B2 (ja) * 1988-03-04 1997-06-11 協和醗酵工業株式会社 抗ｇ−ｃｓｆ誘導体、ｎｄ２８モノクローナル抗体
DK174044B1 (da) * 1986-12-23 2002-05-06 Kyowa Hakko Kogyo Kk Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid.......
US5194592A (en) * 1986-12-23 1993-03-16 Kyowa Hakko Kogyo Co. Ltd. Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US6384194B1 (en) * 1987-12-16 2002-05-07 Dsm N.V. Expression and purification of human interleukin-3 and muteins thereof
GB2213821B (en) * 1987-12-23 1992-01-02 British Bio Technology Synthetic human granulocyte colony stimulating factor gene
US5599690A (en) * 1988-02-01 1997-02-04 Amgen Inc. Control of norleucine incorporation into recombinant proteins
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
US20030232010A2 (en) * 1988-03-29 2003-12-18 Immunomedics, Inc. Improved cytotoxic therapy
WO1989010932A1 (en) * 1988-05-13 1989-11-16 Amgen Inc. Compositions and method for treating or preventing infections in animals
US5070013A (en) * 1988-05-31 1991-12-03 Schering Corporation Immunochemical assay for human granulocyte-macrophage colony stimulating factor
US5082774A (en) * 1988-08-30 1992-01-21 The General Hospital Corporation Recombinant human nerve growth factor
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
ATE135370T1 (de) * 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US6254861B1 (en) * 1989-05-23 2001-07-03 Chandra Choudhury Hematopoietic growth factor derived from T lymphocytes
US5635386A (en) * 1989-06-15 1997-06-03 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
US5763266A (en) * 1989-06-15 1998-06-09 The Regents Of The University Of Michigan Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells
DE69029856T2 (de) * 1989-06-15 1997-09-04 Univ Michigan Verfahren, zubereitungen und anordnungen für zellzucht
US5605822A (en) * 1989-06-15 1997-02-25 The Regents Of The University Of Michigan Methods, compositions and devices for growing human hematopoietic cells
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
US5665543A (en) * 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
US6203976B1 (en) 1989-07-18 2001-03-20 Osi Pharmaceuticals, Inc. Methods of preparing compositions comprising chemicals capable of transcriptional modulation
US5776502A (en) 1989-07-18 1998-07-07 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression
JPH04502164A (ja) * 1989-10-10 1992-04-16 アムジエン・インコーポレーテツド 犬科・猫科動物における感染の治療または予防のための化学組成物及び方法
CA2025181A1 (en) * 1989-10-12 1991-04-13 William G. Weisburg Nucleic acid probes and methods for detecting fungi
US7144731B2 (en) * 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
ATE403713T1 (de) * 1989-10-16 2008-08-15 Amgen Inc Stamzellfaktor
AU6541090A (en) * 1989-10-16 1991-05-16 Amgen, Inc. Stem cell factor
US6852313B1 (en) 1989-10-16 2005-02-08 Amgen Inc. Method of stimulating growth of melanocyte cells by administering stem cell factor
US20040181044A1 (en) * 1989-10-16 2004-09-16 Zsebo Krisztina M. Method of stimulating growth of epithelial cells by administering stem cell factor
ZA907921B (en) 1989-10-16 1991-08-28 Amgen Inc Stem cell factor
US5132212A (en) * 1989-11-17 1992-07-21 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Scl gene, and a hematopoietic growth and differentiation factor encoded thereby
US5214133A (en) * 1989-11-17 1993-05-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SCL: a hematopoietic growth and differentiation factor
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5147799A (en) * 1990-04-25 1992-09-15 Isia Bursuker Repopulation of macrophages and granulocytes using transforming growth factor-beta
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
US5399345A (en) * 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
US5258367A (en) * 1990-06-29 1993-11-02 University Of Florida Uteroferrin and rose proteins for stimulating hematopoietic cells
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
EP0526630A4 (en) * 1991-02-22 1993-08-11 Amgen Inc. Use of gm-csf and g-csf to promote accelerated wound healing
ATE263838T1 (de) * 1991-02-26 2004-04-15 Astrazeneca Ab Vektor
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6413509B1 (en) 1992-11-24 2002-07-02 S. Christopher Bauer Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors
US6153183A (en) 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US7091319B1 (en) 1992-11-24 2006-08-15 Bauer S Christopher IL-3 variant hematopoiesis fusion protein
US6403076B1 (en) 1992-11-24 2002-06-11 S. Christopher Bauer Compositions for increasing hematopoiesis with interleukin-3 mutants
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US5772992A (en) * 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US6361977B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Methods of using multivariant IL-3 hematopoiesis fusion protein
US6361976B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
AU2007200247B2 (en) * 1993-01-28 2011-03-10 Amgen Inc. G-CSF analog compositions
EP0814154B1 (en) 1993-09-15 2009-07-29 Novartis Vaccines and Diagnostics, Inc. Recombinant alphavirus vectors
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
US20050059149A1 (en) * 1993-11-22 2005-03-17 Bauer S. Christopher Methods of ex-vivo expansion of hematopoeitic cells using multivariant IL-3 hematopoiesis chimera proteins
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
TW414799B (en) * 1994-03-31 2000-12-11 Amgen Inc Compositions and methods for stimulating megakaryocyte growth and differentiation
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6100070A (en) * 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
US6066318A (en) * 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
WO1997038087A2 (en) 1996-04-05 1997-10-16 Chiron Corporation Alphaviral vector with reduced inhibition of cellular macromolecular synthesis
RU2113483C1 (ru) * 1996-06-21 1998-06-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Рекомбинантная плазмидная днк pggf 8, кодирующая полипептид со свойствами гранулоцитарного колониестимулирующего фактора человека и штамм бактерий escherichia coli - продуцент полипептида со свойствами гранулоцитарного колониестимулирующего фактора человека
JP2001500738A (ja) 1996-09-17 2001-01-23 カイロン コーポレイション 細胞内疾患を処置するための組成物および方法
US6162426A (en) * 1997-05-05 2000-12-19 La Gamma; Edmund F. Use of G-CSF to enhance the immune system in neonates
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
ES2297889T3 (es) * 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
DE69821011T3 (de) * 1997-10-02 2009-01-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen
US20020034819A1 (en) * 1998-02-23 2002-03-21 Alan K. Smith Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
CN1101403C (zh) * 1998-07-13 2003-02-12 金磊 粒细胞集落刺激因子的制备
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
US5999474A (en) 1998-10-01 1999-12-07 Monolithic System Tech Inc Method and apparatus for complete hiding of the refresh of a semiconductor memory
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
EP2206785A1 (en) 1998-12-31 2010-07-14 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2000040728A1 (en) 1999-01-06 2000-07-13 Xencor, Inc. Nucleic acids and proteins corresponding to mutants of g-csf with granulopoietic activity
US7208473B2 (en) * 1999-01-06 2007-04-24 Xencor, Inc. Nucleic acids and protein variants of hG-CSF with granulopoietic activity
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
JP4682313B2 (ja) 1999-01-19 2011-05-11 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 感染及び炎症をターゲティング及び撮像するための化合物
EA200400067A1 (ru) * 1999-01-29 2004-04-29 Эмджен Инк. Конъюгаты гксф
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
KR100356140B1 (ko) * 1999-07-08 2002-10-19 한미약품공업 주식회사 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6670323B1 (en) 1999-11-12 2003-12-30 Baxter International, Inc. Reduced side-effect hemoglobin compositions
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
DE60139110D1 (de) 2000-01-10 2009-08-13 Maxygen Holdings Ltd G-csf konjugate
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
TR200401573T4 (tr) 2000-02-29 2004-08-23 Pfizer Products Inc. Stabilize edilmiş granülosit koloni uyarıcı faktör
CA2404152C (en) * 2000-03-31 2008-08-05 Celgene Corporation Inhibition of cyclooxygenase-2 activity
JP2003530839A (ja) 2000-04-12 2003-10-21 プリンシピア ファーマスーティカル コーポレイション アルブミン融合タンパク質
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
MXPA03002045A (es) * 2000-09-08 2003-07-24 Amgen Inc Composiciones analogas de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
US20020150979A1 (en) * 2000-10-04 2002-10-17 Naokazu Naitou Process for producing a protein
DE60130799T2 (de) * 2000-11-30 2008-07-17 Children's Medical Center Corp., Boston Synthese von 4-aminothalidomid enantiomeren
EP1229045A1 (en) 2001-02-01 2002-08-07 Institut Curie Universal carrier for targeting molecules to Gb3 receptor expressing cells
JP4279554B2 (ja) 2001-02-19 2009-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔ細胞エピトープの識別方法および低減された免疫原性を有する分子の製造方法
FR2820979B1 (fr) 2001-02-22 2004-03-12 Didier Pourquier Nouvelle application therapeutique du g-csf
US6956023B1 (en) 2001-04-19 2005-10-18 University Of Florida Materials and methods for providing nutrition to neonates
EP1409694A4 (en) 2001-07-05 2006-02-08 Chiron Corp POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF
WO2003004620A2 (en) 2001-07-05 2003-01-16 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
HUP0400466A3 (en) 2001-07-11 2006-01-30 Maxygen Holdings Ltd Georgetow G-csf conjugates
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
ES2742730T3 (es) * 2001-07-31 2020-02-17 Genzyme Corp Métodos de movilización de células progenitoras/madre
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
EP2305313B1 (en) 2001-10-10 2014-03-26 ratiopharm GmbH Remodelling and glycoconjugation of interferon-alpha (IFNa)
SI21102A (sl) 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
KR20030062854A (ko) * 2002-01-21 2003-07-28 주식회사 엘지생명과학 분비형 벡터를 이용한 효모에서의 재조합 단백질의 제조방법
US7557195B2 (en) * 2002-03-20 2009-07-07 Biopolymed, Inc. Stoichiometric conjugates of biocompatible polymers at the unpaired cysteine residue of the wild-type G-CSF
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
AU2003228751A1 (en) 2002-05-01 2003-11-17 Cell Genesys, Inc. Lentiviral vector particles resistant to complement inactivation
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
KR100822149B1 (ko) 2002-05-17 2008-04-15 셀진 코포레이션 암 및 기타 질병의 치료 및 관리를 위해 면역 조절화합물을 이용하는 방법 및 조성물
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
IL165258A0 (en) 2002-05-17 2005-12-18 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US7081443B2 (en) * 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
AU2002345829A1 (en) * 2002-06-24 2004-01-06 Dr. Reddy's Laboratories Ltd. Process for preparing g-csf
SI21273A (sl) * 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
ES2403932T3 (es) 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
EP1539960B1 (en) * 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistant modified interferon alpha polypeptides
EP1900369A1 (en) 2002-10-15 2008-03-19 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
BR0315316A (pt) * 2002-10-15 2005-08-16 Celgene Corp Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
WO2004043378A2 (en) 2002-11-06 2004-05-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
CA2505534A1 (en) * 2002-11-26 2004-06-10 Anthrogenesis Corporation Cytotherapeutics, cytotherapeutic units and methods for treatments using them
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
RU2353385C2 (ru) * 2002-12-31 2009-04-27 Зигнис Байосайенс Гмбх Унд Ко. Кг Способы лечения неврологических состояний с применением гематопоэтических факторов роста
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20040219136A1 (en) * 2003-02-13 2004-11-04 Hariri Robert J Use of umbilical cord blood to treat individuals having a disease, disorder or condition
CA2518584A1 (en) 2003-03-12 2004-09-23 Celgene Corporation 7-amino- isoindolyl compounds and their pharmaceutical uses
AU2004229465B2 (en) * 2003-04-09 2010-04-29 The United States Of America Department Of Veterans Affairs Compositions and methods related to production of erythropoietin
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7501518B2 (en) * 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
EP1615633B1 (en) * 2003-04-22 2012-08-15 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
WO2005018663A1 (en) * 2003-08-22 2005-03-03 The Council Of The Queensland Institute Of Medical Research G-csf derivative for inducing immunological tolerance
UA83504C2 (en) * 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7220407B2 (en) * 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
EA200600921A1 (ru) * 2003-11-06 2006-10-27 Селджин Корпорейшн Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
CA2547570A1 (en) * 2003-12-02 2005-06-23 Celgene Corporation 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for induction of fetal hemoglobin in individuals having anemia
US20060003008A1 (en) 2003-12-30 2006-01-05 Gibson John W Polymeric devices for controlled release of active agents
WO2005074650A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
SE0400942D0 (sv) * 2004-04-08 2004-04-08 Henrik Arnberg Composition and method
MXPA06011798A (es) * 2004-04-14 2007-01-16 Celgene Corp Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de sindromes mielodisplasticos.
EP1744748A4 (en) * 2004-04-14 2009-08-12 Celgene Corp METHOD FOR USE OF SELECTIVE CYTOKINE-INHIBITORY MEDICAMENTS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF MYELODYSPLASTIC SYNDROMES
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
JP2008513356A (ja) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク． 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
AU2005272653A1 (en) * 2004-08-13 2006-02-23 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
AU2005282449B2 (en) 2004-09-07 2011-07-14 Velico Medical, Inc. Apparatus for prolonging survival of platelets
WO2007047687A2 (en) * 2005-10-14 2007-04-26 Zymequest, Inc. Compositions and methods for prolonging survival of platelets
CA2581769C (en) 2004-09-28 2014-03-11 Genexel-Sein, Inc. Methods of using chimeric coiled-coil molecule
GB0505353D0 (en) 2005-03-16 2005-04-20 Chem Technologies Ltd E Treatment process for concrete
CN101072585A (zh) 2004-11-01 2007-11-14 诺华疫苗和诊断公司 产生免疫应答的组合方法
AU2005306894B2 (en) 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
WO2006067170A1 (en) * 2004-12-23 2006-06-29 Laboratoires Serono S.A. G-csf polypeptides and uses thereof
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
JP5735194B2 (ja) 2005-01-25 2015-06-17 セル セラピューティクス インコーポレーテッド 改善された生体内半減期を有する生物学的に活性なタンパク質
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
KR20080027291A (ko) * 2005-06-01 2008-03-26 맥시겐 홀딩스 엘티디 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
DE102005033250A1 (de) † 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
KR100735784B1 (ko) * 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
CN101257926A (zh) * 2005-08-04 2008-09-03 尼克塔治疗亚拉巴马公司 G-csf部分与聚合物的轭合物
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
BRPI0621369A2 (pt) * 2006-02-24 2011-12-06 Genzyme Corp uso de compostos que ligam-se ao receptor quimiocina cxcr4 e métodos para aumentar o fluxo de sangue e promover a regeneração do tecido
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
WO2007102814A2 (en) * 2006-03-07 2007-09-13 Regenetech, Inc. Recombinant mammalian molecules and method for production thereof
GB0605684D0 (en) * 2006-03-21 2006-05-03 Sicor Biotech Uab Method For Purifying Granulocyte-Colony Stimulating Factor
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US8124773B2 (en) 2006-06-12 2012-02-28 Sunesis Pharmaceuticals, Inc. 1,8-naphthyridine compounds for the treatment of cancer
ES2556677T3 (es) 2006-08-02 2016-01-19 Sunesis Pharmaceuticals, Inc. Utilización combinada de ácido (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxílico y citarabina (Ara-C) para el tratamiento de la leucemia
CL2007002218A1 (es) * 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
AU2007281677A1 (en) * 2006-08-07 2008-02-14 Genzyme Corporation Combination therapy
EP2759302A3 (en) 2006-12-21 2014-11-05 Biokine Therapeutics LTD. 4F-benzoyl-TN14003 combined with rituximab for use in the treatment of a tumour
WO2008096370A2 (en) * 2007-02-05 2008-08-14 Natco Pharma Limited An efficient and novel purification method of recombinant hg-csf
MX2009011870A (es) * 2007-05-02 2009-11-12 Ambrx Inc Polipeptidos de interferon beta modificados y usos de los mismos.
US8252822B2 (en) * 2007-07-17 2012-08-28 Acea Biosciences, Inc. Heterocyclic compounds and uses as anticancer agents
WO2009020590A1 (en) * 2007-08-07 2009-02-12 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
EP2185689A2 (en) 2007-08-09 2010-05-19 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
PL2076243T3 (pl) 2007-08-27 2015-04-30 Ratiopharm Gmbh Płynna formulacja G-CSF
CA2696594C (en) 2007-08-27 2019-03-19 Biogenerix Ag Liquid formulation of g-csf conjugate
US8758761B2 (en) * 2007-09-30 2014-06-24 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
KR100921226B1 (ko) 2007-10-04 2009-10-12 학교법인 선목학원 사람 혈액의 과립구집락자극인자(ｈＧ-ＣＳＦ) 유전자를 내장하는 레트로바이러스 발현벡터 및 이에 의해 형질전환된 가금
EP2214824A4 (en) * 2007-11-28 2015-08-19 Smart Tube Inc DEVICES, SYSTEMS AND METHODS FOR DETECTING, STIMULATING, STABILIZING AND ANALYZING A BIOLOGICAL SAMPLE
US20110008371A1 (en) 2007-12-10 2011-01-13 Sunesis Pharmaceuticals, Inc Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
MX2010008632A (es) 2008-02-08 2010-08-30 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
RU2010148803A (ru) * 2008-04-30 2012-06-10 Ньютрон Роу (Bm) Способы применения кортикотропин-рилизинг фактора для лечения рака
DK3782612T3 (da) 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
RU2371112C1 (ru) * 2008-06-30 2009-10-27 Юрий Иванович Зимин Способ профилактики гнойных раневых осложнений у больных онкологического профиля с послеоперационными вентральными грыжами колониестимулирующим фактором "граноцит"
JP5680534B2 (ja) 2008-07-23 2015-03-04 イーライ リリー アンド カンパニー 修飾されているウシｇ−ｃｓｆポリペプチドおよびそれらの使用
EP2396023A2 (en) 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Short beta-defensin-derived peptides
JP5645816B2 (ja) 2009-05-25 2014-12-24 国立大学法人東京工業大学 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
KR101719339B1 (ko) 2009-06-14 2017-03-23 바이오카인 테라퓨틱스 리미티드 혈소판 수준을 증가시키는 펩타이드 요법
EP2445923B1 (en) 2009-06-22 2018-09-05 Amgen, Inc Refolding proteins using a chemically controlled redox state
US20120183536A1 (en) 2009-06-24 2012-07-19 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the treatment of cancer
EP2445924B2 (en) 2009-06-25 2023-12-13 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
TW201120037A (en) 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
US20110129858A1 (en) * 2009-11-27 2011-06-02 Changhua Christian Hospital Prognosis Biomarker for Evaluating the Cure Level of Stroke Patient and a Method thereof
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
DK2341061T3 (da) 2009-12-31 2013-11-04 Arven Ilac Sanayi Ve Ticaret As Ny fremgangsmåde til fremstilling af G-CSF (granulocytkoloni-stimulerende faktor)
CN102822173A (zh) * 2010-02-19 2012-12-12 美国艾森生物科学公司 杂环化合物和作为抗癌剂的用途
WO2011109556A2 (en) 2010-03-04 2011-09-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
CA2792872A1 (en) * 2010-03-12 2011-09-15 Celgene Corporation Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
WO2011123570A2 (en) 2010-04-01 2011-10-06 Pfenex Inc. Methods for g-csf production in a pseudomonas host cell
CA2807552A1 (en) * 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
EP2621515B1 (en) 2010-09-28 2017-03-29 Aegerion Pharmaceuticals, Inc. A chimeric seal-human leptin polypeptide with increased solubility
WO2012078492A1 (en) 2010-12-06 2012-06-14 Celgene Corporation A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
EP2670396A1 (en) 2011-01-31 2013-12-11 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
PH12013501820A1 (en) 2011-03-11 2013-11-25 Celgene Corp Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
PL2683708T3 (pl) 2011-03-11 2018-03-30 Celgene Corporation Postacie stałe 3-(5-amino-2-metylo-4-okso-4h-chinazolin-3-ylo)-piperydyno-2,6-dionu oraz ich kompozycje farmaceutyczne i zastosowania
CN103688176A (zh) 2011-04-29 2014-03-26 细胞基因公司 利用cereblon作为预报因子治疗癌和炎性疾病的方法
US9320777B2 (en) 2011-05-13 2016-04-26 Bolder Biotechnology, Inc. Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
US10350139B2 (en) 2011-10-25 2019-07-16 Corning Incorporated Pharmaceutical glass packaging assuring pharmaceutical sterility
EP2771295B1 (en) 2011-10-25 2017-11-22 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
PH12014500965A1 (en) 2011-11-01 2014-06-30 Celgene Corp Methods for treating cancers using oral formulations of cytidine analogs
US8889630B2 (en) 2011-12-23 2014-11-18 Carlos Lopez Method for hair regrowth using Granulocyte-Colony Stimulating Factor
HUP1200172A2 (en) 2012-03-19 2013-10-28 Richter Gedeon Nyrt Methods for refolding g-csf from inclusion bodies
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
ES2681050T3 (es) 2012-04-11 2018-09-11 Acerta Pharma B.V. Inhibidores de la tirosina quinasa de Bruton para la movilización hematopoyética
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
EP3489682B1 (en) 2012-06-29 2021-03-31 Celgene Corporation Methods for determining drug efficacy using ikzf3 (aiolos)
US9732144B2 (en) 2012-07-05 2017-08-15 Ohio State Innovation Foundation Infectious bursal disease (IBDV) vaccine compositions
EP2879710B1 (en) 2012-08-03 2019-11-13 Dana-Farber Cancer Institute, Inc. Medical uses of agents that modulate immune cell activation and corresponding screening methods
MX367869B (es) 2012-08-09 2019-09-10 Celgene Corp Metodos de tratamiento de cancer usando 3-(4((4-(morfolinometil) bencil) oxi)-1-oxoisoindolin-2-il) piperidin-2, 6-diona.
US9221788B2 (en) 2012-08-09 2015-12-29 Celgene Corporation Salts and solid forms of (S)-3-(4- (4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
SG11201501653RA (en) 2012-09-10 2015-04-29 Celgene Corp Methods for the treatment of locally advanced breast cancer
US9968627B2 (en) 2013-03-26 2018-05-15 Celgene Corporation Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof
CN105246480A (zh) 2013-04-02 2016-01-13 细胞基因公司 使用4-氨基-2-(2,6-二氧代-哌啶-3-基)-异吲哚啉-1,3-二酮治疗和控制中枢神经系统癌症的方法和组合物
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9713572B2 (en) 2013-04-24 2017-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717648B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717649B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707153B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707155B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3293275B1 (en) 2013-06-06 2021-08-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
WO2015057992A1 (en) 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
EP3068891A1 (en) 2013-11-13 2016-09-21 Aequus Biopharma Inc. Engineered glycoproteins and uses thereof
EP3094736A4 (en) 2014-01-14 2017-10-25 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
US20150359810A1 (en) 2014-06-17 2015-12-17 Celgene Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
EP3160486B1 (en) 2014-06-27 2020-11-18 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
CA2958867A1 (en) 2014-08-22 2016-02-25 Anjan THAKURTA Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
MA40517A (fr) 2015-03-16 2016-09-21 Arven Ilac Sanayi Ve Ticaret As Procédé pour préparation du facteur stimulant les colonies de granulocytes (g-csf)
WO2016167291A1 (ja) 2015-04-13 2016-10-20 国立研究開発法人産業技術総合研究所 環状化サイトカイン及びその製法
HUE065109T2 (hu) 2015-06-26 2024-05-28 Celgene Corp Eljárások Kaposi-szarkóma vagy KSHV-indukált limfóma kezelésére immunomodulátor vegyületek alkalmazásával, valamint biomarkerek alkalmazása
KR20210089270A (ko) 2015-07-16 2021-07-15 바이오카인 테라퓨틱스 리미티드 암 치료용 조성물 및 방법
WO2017040387A2 (en) 2015-08-31 2017-03-09 Technovax, Inc. Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
US11229683B2 (en) 2015-09-18 2022-01-25 Bolder Biotechnology, Inc. Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
EP3362074B1 (en) 2015-10-16 2023-08-09 President and Fellows of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
US10947287B2 (en) 2015-10-19 2021-03-16 Sandoz Ag DNA coding sequence for human G-CSF
AU2016342210A1 (en) 2015-10-19 2018-05-10 Sandoz Ag Method for producing a recombinant protein with reduced impurities
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP6864296B2 (ja) 2015-12-14 2021-04-28 エックス４ ファーマシューティカルズ， インコーポレイテッド がんを処置する方法
EP3393468B1 (en) 2015-12-22 2022-09-14 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
US10189808B2 (en) 2016-01-08 2019-01-29 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
CA3010797C (en) 2016-01-08 2024-01-02 Celgene Corporation Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
DK3399978T3 (da) 2016-01-08 2020-11-16 Celgene Corp Antiproliferative forbindelser og farmaceutiske sammensætninger dermed og anvendelser deraf
US10993985B2 (en) 2016-02-23 2021-05-04 BioLmeRx Ltd. Methods of treating acute myeloid leukemia
CN110753755B (zh) 2016-03-21 2023-12-29 丹娜法伯癌症研究院 T细胞耗竭状态特异性基因表达调节子及其用途
CA3018986A1 (en) 2016-04-01 2017-10-05 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
PT3436019T (pt) 2016-04-01 2021-11-04 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017180770A1 (en) 2016-04-13 2017-10-19 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
CA3027495A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CA3027498A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
WO2018013693A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
WO2018013689A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
MX2019004499A (es) 2016-10-17 2019-11-18 Janssen Pharmaceuticals Inc Star Sistemas de replicón de virus recombinante y usos de estos.
BR112019011661A2 (pt) 2016-12-05 2020-01-07 Synthetic Genomics, Inc. Composições e métodos para aumentar expressão de gene
WO2018165142A1 (en) 2017-03-07 2018-09-13 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
MX2019014875A (es) 2017-06-21 2021-01-29 SHY Therapeutics LLC Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
HRP20230210T1 (hr) 2017-06-30 2023-04-14 Celgene Corporation Pripravci i postupci upotrebe 2-(4-klorofenil)-n-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il)metil)-2,2-difluoroacetamida
WO2019070827A1 (en) 2017-10-04 2019-04-11 Celgene Corporation PROCESSES FOR THE PREPARATION OF CIS-4 [2 - {(3S, 4R) -3-FLUOROOXAN-4-YL] AMINO) -8- (2,4,6-TRICHLOROANILINO) -9H-PURIN-9-YL] -1 -MÉTHYLCYCLOHEXANE-1-carboxamide
IL273658B2 (en) 2017-10-04 2024-10-01 Celgene Corp Compositions and methods of use of cis-4-[2-{[(3s,4r)-3-fluorooxan-4-yl] amino}-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide
AR113756A1 (es) * 2017-10-11 2020-06-10 Ambrx Inc Variantes porcinas de g-csf y sus usos
KR20200104291A (ko) 2017-11-06 2020-09-03 랩트 테라퓨틱스, 인크. 항암제
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
JP7494117B2 (ja) 2018-01-19 2024-06-03 ヤンセン ファーマシューティカルズ，インコーポレーテッド 組換えレプリコン系を使用する免疫応答の誘導および増強
CN112888435A (zh) 2018-08-22 2021-06-01 纪念斯隆-凯特琳癌症中心 联合疗法治疗神经母细胞瘤的方法
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US12331076B2 (en) 2018-10-08 2025-06-17 Janssen Pharmaceuticals, Inc. Alphavirus-based replicons for administration of biotherapeutics
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2020234742A1 (en) 2019-05-20 2020-11-26 Lupin Limited Granulocyte colony stimulating factor purification
PE20221155A1 (es) 2019-11-05 2022-07-18 Celgene Corp Terapia de combinacion con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
CN115515585A (zh) 2020-03-10 2022-12-23 X4 制药有限公司 用于治疗中性粒细胞减少症的方法
WO2021257828A1 (en) 2020-06-18 2021-12-23 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
AU2023252917A1 (en) 2022-04-14 2024-11-28 Bristol-Myers Squibb Company Novel gspt1 compounds and methods of use of the novel compounds
WO2024064646A1 (en) 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same
WO2025085416A1 (en) 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
WO2025109150A1 (en) 2023-11-24 2025-05-30 Ludwig-Maximilians-Universität München, In Vertretung Des Freistaates Bayern The combination of gm-csf and inhibition of ccl22-ccr4 signaling in the treatment of cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358535A (en) * 1980-12-08 1982-11-09 Board Of Regents Of The University Of Washington Specific DNA probes in diagnostic microbiology
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
JPS6023777A (ja) * 1983-07-15 1985-02-06 鶴海合成炉材株式会社 低融点金属用溶解保持手許炉
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4710473A (en) * 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS60206066A (ja) * 1984-03-29 1985-10-17 Toshiba Corp 固体撮像装置
JPS60209638A (ja) * 1984-04-03 1985-10-22 Diesel Kiki Co Ltd デイ−ゼル機関用電子式ガバナ
JPS60217150A (ja) * 1984-04-13 1985-10-30 マツダ株式会社 塗装を施した繊維強化ウレタン成形品
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
ATE65798T1 (de) * 1985-02-08 1991-08-15 Chugai Pharmaceutical Co Ltd Menschlicher granuloxcyt-koloniestimulierungsfaktor.
JPH0615477B2 (ja) * 1985-02-08 1994-03-02 中外製薬株式会社 感染防禦剤
JPH01110629A (ja) * 1985-04-05 1989-04-27 Chugai Pharmaceut Co Ltd 感染防禦剤
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS62236497A (ja) * 1985-09-17 1987-10-16 Chugai Pharmaceut Co Ltd 顆粒球コロニー刺激因子活性を有する糖蛋白質の製造方法
EP0220520B1 (en) * 1985-09-30 1991-09-18 Chugai Seiyaku Kabushiki Kaisha Human granulocyte colony stimulating factor
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
JP2976258B2 (ja) * 1992-07-07 1999-11-10 株式会社名機製作所 ホットプレスの断熱材取付け構造

Also Published As

Publication number Publication date
NZ217334A (en) 1991-05-28
JP2660179B2 (ja) 1997-10-08
CY1642A (en) 1992-11-06
SG48964A1 (en) 1998-05-18
JP2952203B2 (ja) 1999-09-20
HK1029600A1 (en) 2001-04-06
DK204487D0 (da) 1987-04-22
FI20000014L (fi) 2000-01-04
JP3115561B2 (ja) 2000-12-11
NO871679D0 (no) 1987-04-22
JPH0231675A (ja) 1990-02-01
NO2003008I1 (no) 2004-01-05
KR880700071A (ko) 1988-02-15
MX9202992A (es) 1992-07-01
NO20032250L (no) 1987-04-22
US5580755A (en) 1996-12-03
DK204487A (da) 1987-04-22
IL79805A0 (en) 1986-11-30
JPH042599B2 (no) 1992-01-20
JPH08231412A (ja) 1996-09-10
EP0237545B2 (en) 1999-08-25
FI871700A0 (fi) 1987-04-16
JP2002315578A (ja) 2002-10-29
FI871700A7 (fi) 1987-04-16
GR862185B (en) 1986-12-23
JP2006101889A (ja) 2006-04-20
JP2527365B2 (ja) 1996-08-21
EP0237545A1 (en) 1987-09-23
DK174980B1 (da) 2004-04-05
NO20032250D0 (no) 2003-05-19
NO20045548L (no) 1987-04-22
JP2000279185A (ja) 2000-10-10
CN86106234A (zh) 1987-06-17
SA92130186B1 (ar) 2006-09-09
FI107540B (fi) 2001-08-31
US4810643A (en) 1989-03-07
NO314902B1 (no) 2003-06-10
ES2001883A6 (es) 1988-07-01
IL79805A (en) 1991-12-15
EP0237545B1 (en) 1991-05-22
NO982132L (no) 1987-04-22
SG35892G (en) 1992-05-22
NO2003010I1 (no) 2004-01-26
DE3650788D1 (de) 2006-08-17
FI110576B (fi) 2003-02-28
FI105191B (fi) 2000-06-30
JPH11276168A (ja) 1999-10-12
NL930127I1 (nl) 1993-11-01
AU6334686A (en) 1987-03-10
JP2718426B2 (ja) 1998-02-25
CA1341537C (en) 2007-07-31
WO1987001132A1 (en) 1987-02-26
JP2660178B2 (ja) 1997-10-08
JPH09224670A (ja) 1997-09-02
PT83242B (pt) 1988-07-01
NO318755B1 (no) 2005-05-02
NO871679L (no) 1987-04-22
US5830705A (en) 1998-11-03
ATE332375T1 (de) 2006-07-15
JPH06181791A (ja) 1994-07-05
EP0237545A4 (en) 1987-12-17
PT83242A (en) 1986-09-01
DE3650788T2 (de) 2007-06-14
US5582823A (en) 1996-12-10
JP2004041242A (ja) 2004-02-12
JPH0242998A (ja) 1990-02-13
NO303544B1 (no) 1998-07-27
NO982132D0 (no) 1998-05-11
US5676941A (en) 1997-10-14
FI20010334L (fi) 2001-02-21
CN1020924C (zh) 1993-05-26
JPH0690751A (ja) 1994-04-05

Similar Documents

Publication Publication Date Title
NO2003010I2 (no) Pegfilgrastim
ES8802329A1 (es) Un procedimiento para preparar un polipetido que tiene en parte o en su totalidad la conformacion estructural primaria de la critropoyetina de origen natural.
BR8206068A (pt) Composicoes de materia,polipeptideo,sequencia de dna,veiculo de expressao replicavel,microorganismo ou cultura celular,plasmideo,extrato de cultura celular,cultura de celulas transformantes,uso de interferon imune humano maduro,processo de expressao de um gene,processo para producao de um polipeptideo,processo para producao de um veiculo de expressao,e produto obtido por tais processos
HUT60769A (en) Process for producing polypeptides
IL88151A (en) Interleukin-7 protein, dna sequences encoding it, its preparation and compositions containing it
EP0275204A3 (en) Production of fibroblast growth factor
ES2088911T3 (es) Gen de la proteasa i de achromobacter y el producto de este gen.
Souza Methods of treating bacterial inflammation and granulocytopoiesis by administering human pluripotent granulocyte colony-stimulating factor
FI852377L (fi) Menetelmä erytropoietiinin valmistamiseksi ja siinä käytettyjä DNA-sekvenssejä
JPS6437291A (en) Human cytochrome c gene and use thereof
CA2324649A1 (en) Human p51 genes and gene products thereof
DK365185A (da) Fremstilling af erythropoietin.

Legal Events

Date Code Title Description
MK1K Patent expired